Humanin.
Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome.
Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome. Humanin is research / preclinical, and PepCue grades its published evidence F tier (28/100). This is a research reference, not medical or dosing advice.
What it is
Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome. Its coding sequence sits inside the mitochondrial 16S ribosomal RNA region (MT-RNR2), and a near-identical nuclear-encoded form also exists. It was discovered in 2001 by Hashimoto and colleagues in Ikuo Nishimoto's lab at Keio University during a cDNA screen for factors that protected neurons from Alzheimer's-disease-related insults, and it is studied primarily as a cytoprotective and metabolic signaling peptide.
How it works
Humanin acts both intracellularly and as a secreted, receptor-mediated factor. Intracellularly it binds and antagonizes the pro-apoptotic Bcl-2-family proteins BAX, tBID and BimEL, blocking their translocation to mitochondria and suppressing apoptosis. Extracellularly it signals through a tripartite cytokine-like receptor complex (CNTF receptor / WSX-1 / gp130) that activates STAT3, and also engages formyl-peptide receptors (FPRL1/FPR2). It modulates insulin/IGF-1 signaling, interacting with IGFBP-3 and enhancing AKT phosphorylation, and acts centrally in the hypothalamus as an insulin sensitizer; the engineered S14G analog (HNG) is far more potent than the native peptide in preclinical assays.
Mechanism pathways
Mitochondria-derived and mitochondria-targeted peptides in metabolism and stress responses.
Mitochondria are not only the site of oxidative phosphorylation; they are also signalling organelles that communicate their status to the rest of the cell and, through circulating factors, to the rest of the body. Two distinct classes of peptide are grouped here, and the distinction matters because they are quite different things. The first class is peptides encoded within mitochondrial DNA itself, in short open reading frames inside genes normally read as ribosomal RNA. These are genuinely mitochondria-derived and act as signalling molecules. One has been described as a stress-responsive regulator that activates the AMP-activated protein kinase energy-sensing pathway, influences folate and methionine one-carbon metabolism, and under metabolic stress translocates to the cell nucleus where it is proposed to help direct adaptive antioxidant gene expression. Another acts both inside and outside the cell: intracellularly it binds and antagonises pro-apoptotic Bcl-2 family proteins, preventing their translocation to mitochondria and suppressing programmed cell death, and extracellularly it signals through a cytokine-like receptor complex that activates STAT3 and engages formyl peptide receptors. It also interacts with insulin and IGF-1 signalling. Circulating levels of both have been described as declining with age, which is the observation driving interest in them. The second class is not mitochondria-derived but mitochondria-targeted by design. A peptide with an alternating aromatic and cationic motif carries a net positive charge that drives selective accumulation in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid found almost exclusively there. By associating with cardiolipin it is proposed to stabilise cristae architecture, protect the interaction between cardiolipin and cytochrome c, and support electron-transport-chain organisation and membrane potential. This is a structural stabilisation mechanism rather than a receptor-mediated signal, and it is why the compound is described as improving mitochondrial efficiency rather than stimulating it. Honest assessment: this is an active and legitimate research field with well-characterised molecular interactions, but the characterisation is predominantly in cell and animal systems. Human clinical evidence is limited, and the mitochondria-targeted compound has been through clinical trials in specific conditions without producing a clearly positive result in every setting. None of these is an approved medicine, and none should be described as an established treatment for age-related decline or metabolic disease.
The evidence
The strongest data are preclinical. In cell and rodent models, humanin and HNG reduce neuronal death from amyloid-beta and other insults, shrink infarct size in stroke models, improve glucose handling, and reduce age-related cognitive decline in mice (Yen et al., Scientific Reports 2018; Hashimoto et al., J Neurosci 2001). Human evidence is observational, not interventional: circulating humanin declines with age, is lower in conditions such as Alzheimer's disease and the mitochondrial disorder MELAS, and higher levels have been associated with better "cognitive age" and with longevity-enriched cohorts (long-lived offspring, centenarians). Critically, there are no published randomized controlled trials of exogenous humanin or HNG in humans, and no completed published Phase 1 safety trial, so therapeutic benefit in people remains unproven and the human-versus-animal gap is large.
The evidence, in brief
A mitochondrial-derived peptide first identified for protecting neurons against amyloid-β toxicity, with cytoprotective activity across metabolic and neurodegenerative models. Evidence is predominantly preclinical and biomarker/observational in humans; no approved therapies or pivotal trials.
- Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases (review)Expert Opin Ther Targets, 2019 (PMID 30582721)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #031
Mostly preclinical or mechanistic; little human data.
Findings come mainly from animal models, not people.
Claim receipts
Popular claims about Humanin, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Lifespan and healthspan signals come from cell and rodent work; human data is observational rather than interventional.
Neuroprotection findings are from cell and rodent models of amyloid and ischemic injury, not from human trials.
Higher circulating levels in long-lived cohorts is an association, and no trial has tested whether administering the peptide reproduces it.
No controlled human trial of the administered peptide has been completed and published, so tolerability, immunogenicity and long-term effects are unknown.
Safety profile
Because no controlled human trials of administered humanin or HNG have been completed and published, the human safety profile is essentially unknown, including immunogenicity, dosing tolerability, and long-term effects. As a STAT3-activating, anti-apoptotic and growth-signaling peptide, theoretical concerns include effects on cell survival and proliferation pathways, but these have not been characterized clinically. Material sold online as "humanin" is research-use-only chemical of unverified identity and purity, not a pharmaceutical product, adding contamination and mislabeling risks. No safety conclusions for human use can be drawn from the existing animal and cell data.
Compound notes
- Humanin is a mitochondrial-derived peptide with cytoprotective signaling.
- It is studied preclinically for neuroprotection and metabolic/aging effects.
- Not FDA-approved; research-only.
- Human evidence is minimal; longevity claims are preclinical.
Regulatory status
Humanin and its analog HNG are not approved by the FDA, EMA, or any major regulator for any indication; they are investigational/research-use-only compounds with no completed published Phase 1 human trial. They are not established WADA-prohibited substances by name, but exogenous peptides with growth-factor-like signaling can fall under broad anti-doping categories, so status should not be assumed.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01One of the first mitochondrial-derived peptides (MDPs), encoded within the 16S rRNA (MT-RNR2) region of mitochondrial DNA
- 02Discovered in 2001 by Hashimoto/Nishimoto from a screen for neuroprotective factors in Alzheimer's-affected brain tissue
- 03Acts via intracellular BAX/BID/Bim antagonism and extracellular CNTFR/WSX-1/gp130-STAT3 and FPR2 receptor signaling
- 04Circulating levels decline with age and are lower in Alzheimer's disease and MELAS in human observational studies
- 05The S14G analog (HNG) is dramatically more potent than native humanin in preclinical neuroprotection assays
- 06No completed published randomized human clinical trial; human evidence is associational only
Humanin: research formats
Choose the format you are researching to see route-specific notes.
No completed published human trial, so no route, schedule, or human safety profile exists.
Humanin is a 24-amino-acid mitochondrial-derived peptide discovered in 2001 during a screen for factors protecting neurons from Alzheimer's-related insults. The human evidence is associational: circulating levels decline with age and are lower in Alzheimer's disease and MELAS. No controlled human trial of administered humanin or its S14G analog (HNG) has been completed and published, so this page presents no administration format.
Because no human trial has been completed, immunogenicity, tolerability, and long-term effects are all unknown. Observational data about naturally circulating levels says nothing about what injecting the peptide does.
Humanin and HNG are not approved by any major regulator. They are not WADA-listed by name, but exogenous peptides with growth-factor-like signaling can fall under broad anti-doping categories, so status should not be assumed.
Sources
Every factual claim above resolves to a real, published source.
- Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insultsJournal of Neuroscience, 2001, PMID 11717357 (Hashimoto Y et al.)
- The emerging role of the mitochondrial-derived peptide humanin in stress resistanceJournal of Molecular Endocrinology, 2013, PMID 23239898 (Yen K et al.)
- Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in HumansScientific Reports, 2018, PMID 30242290 (Yen K et al.)
- The mitochondrial derived peptide humanin is a regulator of lifespan and healthspanAging (Albany NY), 2020, PMID 32575074 (Yen K et al.)
Cite this page
PepCue. “Humanin: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/humanin.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.